Sigvotatug vedotin — Investigational Agent
Antibody-Drug Conjugate · Phase 3 · Pfizer (Seagen)
Mechanism of Action
Sigvotatug vedotin is an ADC targeting integrin beta-6 (ITGB6), a cell-surface integrin subunit overexpressed on many epithelial carcinomas including NSCLC. The antibody is conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent, via a protease-cleavable linker. Upon binding integrin beta-6 the ADC is internalized and MMAE is released, causing microtubule disruption, G2/M cell-cycle arrest and apoptosis. Released MMAE also mediates a bystander effect on neighboring tumor cells.
Investigational Indications
- Previously treated advanced non-small cell lung cancer
- First-line NSCLC in combination with immunotherapy